Tumor-Specific Activity of Precision Medicines in the NCI-MATCH Trial

Through a subgroup analysis of published subprotocols of the NCI-MATCH oncology basket trial, we found instances in which one tumor type responded better to the targeted therapy than others in the subprotocol.

Starting in 2021, I worked with Dr. Deb Plana and Dr. Adam Palmer on a subgroup analysis of published subprotocols of the NCI-MATCH oncology basket trial. We applied permutation testing to analyze published data on tumor change and progression-free survival, then performed the Benjamini-Hochberg procedure to control the false discovery rate.

Zhou I, Plana D, Palmer AC. Tumor-specific activity of precision medicines in the NCI-MATCH trial. Clinical Cancer Research. Published online December 18, 2023. doi:https://doi.org/10.1158/1078-0432.ccr-23-0983